Japan Market Report for Coronary Stents 2018 - MedCore

Japan Market Report for Coronary Stents 2018 - MedCore

  • October 2017 •
  • 671 pages •
  • Report ID: 5365742 •
  • Format: PDF
General Report Contents
- Market Analyses include: Unit Sales, ASPs, Market Value & Growth Trends
- Market Drivers & Limiters for each chapter segment
- Competitive Analysis for each chapter segment
- Section on recent mergers & acquisitions

Angioplasty procedures are performed only after a problem has been detected by a diagnostic procedure, such as X-ray based angiography. In addition to stents, angioplasty procedures utilize a number of accessory products including introducer sheaths, PTCA balloon catheters, interventional catheters and guidewires, diagnostic catheters and guidewires, atherectomy devices, chronic total occlusion (CTO) devices, vascular closure devices (VCD), intravascular ultrasound (IVUS) catheters and optical coherence tomography (OCT) catheters.

As of 2017, there are three main types of stents used for coronary applications: bare-metal,
drug-eluting and bioabsorbable stents. Bare-metal stents (BMS) consist of a wire mesh that is designed to expand and keep the lumen from closing again. BMS were introduced in 1994 by Johnson & Johnson and within a few years, millions of these devices were being placed worldwide. Because minimally invasive procedures such as angioplasties are faster, easier to perform, safer and less expensive than CABG procedures, far more patients could be treated than prior to stent introduction. After a few years of use, it was found that bare-metal stents, while effective at dilating arteries, were associated with a substantial risk of restenosis, where the arterial wall would heal over the stent and occlude the artery again.

Restenosis requires an additional stenting or CABG procedure to be performed, dramatically increasing costs as well as the risk to the patient. To counter the risk of restenosis, drug-eluting stents (DES) were developed. These stents are coated with a polymer containing a drug that inhibits healing and reduces the rate of restenosis.

Abstract
Percutaneous transluminal coronary angioplasty (PTCA) is the preferred method for the treatment of patients suffering from angina or myocardial infarction (MI). The procedure is generally considered to be more effective than drugs and less invasive than coronary artery bypass graft (CABG) surgery. Angioplasty procedures are performed to dilate a blocked lumen of an artery and restore blood circulation. These procedures involve inserting a PTCA catheter into the femoral, radial or brachial arteries and extending the catheter across the targeted lesion to position the stent.

Scope
2014-2024